Single nucleotide polymorphisms that suppress FPR1 signaling are associated with decreased survival in patients receiving adjuvant chemotherapy for breast cancer, suggesting that FPR1 is important for the antitumor immune response to chemotherapy [60]. This evidence concerns the gene FPR1 and breast carcinoma.